Unimedic Pharma
- Company typePrivate
- Founded1992
- HeadquartersStockholm, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Unimedic Pharma does
Unimedic Pharma AB is a Swedish specialty pharmaceutical company headquartered in Solna (Stockholm) and operating across the four Nordic countries (Sweden, Norway, Finland, Denmark). Founded in 1992 and wholly-owned by the listed parent MedCap AB (publ) since 2006, the company runs an integrated Nordic commercialization platform covering three business areas: registered proprietary specialty pharmaceuticals across therapeutic areas including emergency care, pain, infectious diseases, gastroenterology, urology, ADHD and substance abuse; partner products where Unimedic serves as Marketing Authorization Holder (MAH) or local representative for international pharma companies lacking Nordic presence; and unlicensed pharmaceuticals (licensläkemedel), in which segment the company claims Swedish market leadership. The company also owns Unimedic AB, a CDMO subsidiary in Matfors (outside Sundsvall) that manufactures liquid pharmaceuticals (sterile and non-sterile) for both the group and external customers, and acquired Copenhagen-based XGX Pharma in 2025 to expand its Danish footprint.
The business model combines product sales (proprietary and partner pharmaceuticals distributed via a Nordic field sales organization), out-licensing of proprietary products to partners outside the Nordics (generating royalties), and procurement/distribution of unlicensed medicines for Swedish prescribers when no licensed alternative exists. Pricing for registered products is set through reimbursement negotiations with national health authorities in each Nordic country; unlicensed and CDMO revenues are transaction-based. The company employs approximately 40 staff at its Stockholm headquarters, supported by manufacturing operations in Matfors and the newly acquired Danish entity. Key partner relationships include distribution and commercialization agreements with Infectopharm, Basilea, Viatris, Pascoe, Twinpharma, Ethypharm, and AcuCort (whose Zeqmelit® product generated a EUR 112,000 Nordic order in late 2025).
The company generated approximately 318 million SEK in FY2024 turnover, making it a small but operationally integrated Nordic specialty pharma platform with unusually broad functional coverage (regulatory, market access, QA, pharmacovigilance, sales) for its headcount, enabled by its vertically integrated CDMO subsidiary and decades-long relationships with international pharma partners seeking Nordic entry.
Unimedic Pharma firmographics
Firmographics- Name
- Unimedic Pharma
- Legal name
- Unimedic Pharma AB
- Website
- https://unimedicpharma.se
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Unimedic Pharma is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices3 records
Markets served
Unimedic Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Registered Specialty Pharmaceuticals Sales: Sale of proprietary and partner-licensed registered specialty pharmaceuticals across the Nordic region within therapeutic areas including emergency care, pain management, infectious diseases, gastroenterology, urology, ADHD and substance abuse. Revenue is generated through direct sales to healthcare providers and pharmacies via field-based sales teams.
- Unlicensed Pharmaceuticals Distribution: Sweden's leading supplier of unlicensed pharmaceuticals — pharmaceuticals that are not available as licensed products in Sweden but are approved in other countries. Revenue is generated from the procurement and distribution of these pharmaceuticals to prescribers (doctors/veterinarians) when licensed alternatives are unavailable or out of stock.
- Out-licensing of Proprietary Products: Unimedic Pharma offers business opportunities through out-licensing of proprietary products to partners in markets outside the Nordic region, generating licensing/royalty revenue.
- Commercial Partnership Representation (MAH/Agent): As MAH (Marketing Authorization Holder) or local representative, Unimedic commercializes partner companies' pharmaceutical products in the Nordic region, earning commissions or margin on sales.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Prescription specialty pharmaceuticals — pricing determined by national reimbursement authorities in each Nordic country. |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Unimedic Pharma product offering
Product offeringCore offering
Unimedic Pharma is a Swedish specialty pharmaceutical company that commercializes registered specialty pharmaceuticals, partner products, and unlicensed pharmaceuticals across the Nordic region (Sweden, Norway, Finland, Denmark). The company specializes in registering, launching, and marketing pharmaceuticals on the Nordic market through an integrated platform covering regulatory affairs, market access, distribution, marketing, quality assurance, pharmacovigilance, and field-based sales, and operates Unimedic AB, an in-house CDMO for liquid pharmaceutical manufacturing.
Product overview
Unimedic Pharma is a Swedish specialty pharma company operating as part of Unimedic Group (owned by MedCap AB). The company offers three main business areas: (1) Proprietary pharmaceuticals and products - registered specialist pharmaceuticals within therapeutic areas such as emergency care, pain management, gastroenterology, urology, and ADHD; (2) Partner products - pharmaceuticals from other companies where Unimedic serves as MAH or local representative in the Nordic region; (3) Unlicensed pharmaceuticals (licensläkemedel) - medicines not available in Sweden but approved in other countries. The company also owns XGX Pharma (Danish specialist pharma company based in Copenhagen) and has an associated company Unimedic AB (CDMO) for contract manufacturing. Specific products include Zeqmelit® (distributed from AcuCort) and various portfolio products in emergency care, infectious diseases, and substance abuse. The company has partnerships with Infectopharm, Basilea, Viatris, Pascoe, Twinpharma, Ethypharm, and AcuCort.
Differentiator
Problem solved
Functional benefit
Products and services
- Zeqmelit®
- Proprietary & Registered Specialty Pharmaceuticals Portfolio
Quantifiable outcome
- EUR 112,000 order from AcuCort for Zeqmelit® covering Nordic market (Q2 2026)
Companies that use Unimedic Pharma
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles4 records
Unimedic Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Unimedic Pharma partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- XGX PharmacoreXGX Pharma is a Danish specialist pharmaceutical company based in Copenhagen that was acquired by Unimedic Pharma in 2025. The acquisition strengthens Unimedic Pharma's position as a leading player in the Nordic specialty pharmaceuticals market, expanding its geographic presence in Denmark.
- InfectopharmcoreInfectopharm is a pharmaceutical partner whose products are distributed by Unimedic Pharma in the Nordic region. Unimedic Pharma serves as the commercial partner handling registration, market access, marketing, and sales for Infectopharm's portfolio in the Nordics.
- BasileacoreBasilea is a pharmaceutical partner whose products are distributed by Unimedic Pharma in the Nordic region. Unimedic Pharma serves as the commercial partner handling registration, market access, marketing, and sales for Basilea's portfolio in the Nordics.
- ViatriscoreViatris is a global pharmaceutical company whose products are distributed by Unimedic Pharma in the Nordic region through a commercial partnership arrangement.
- PascoeminorPascoe is a pharmaceutical partner whose products are distributed by Unimedic Pharma in the Nordic region through a distribution partnership.
- TwinpharmaminorTwinpharma is a pharmaceutical partner whose products are distributed by Unimedic Pharma in the Nordic region.
- EthypharmcoreEthypharm is a pharmaceutical partner whose products are distributed by Unimedic Pharma in the Nordic region, representing a strategic partnership in specialty pharmaceuticals.
- AcuCortcoreUnimedic Pharma is the Nordic distribution partner for AcuCort's Zeqmelit® product. AcuCort received an order from Unimedic Pharma valued at EUR 112,000 covering the Nordic market, with expected positive financial impact in Q2 2026. Unimedic handles all commercial activities for Zeqmelit® in the Nordics.
- Unimedic ABcoreUnimedic AB is the CDMO (Contract Development and Manufacturing Organisation) subsidiary of the Unimedic Group, specializing in production and development of liquid pharmaceuticals (sterile and non-sterile). Located in Matfors, outside Sundsvall, it manufactures the Group's proprietary pharmaceuticals and offers contract manufacturing services to external pharma companies.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Unimedic Pharma competitors and assessment
Company assessmentDirect peers
- Orexo AB: Swedish specialty pharma company commercializing proprietary products in opioid dependence and pain — therapeutic areas that overlap directly with Unimedic's substance abuse and pain management portfolio. Comparable scale and Nordic commercialization approach.
- Camurus AB: Swedish specialty pharma developing and commercializing proprietary niche pharmaceutical products across multiple therapeutic areas. Highly comparable in scale, Nordic footprint and proprietary-product commercialization model.
- Recipharm AB: Swedish-headquartered CDMO offering contract development and manufacturing of liquid and other dosage forms. Directly comparable to Unimedic AB's CDMO business, with similar therapeutic focus on liquid pharmaceuticals.
- Oriola Corporation: Finnish-based pharmaceutical distributor operating across the Nordic region with comparable geographies, supplying pharmacies and healthcare providers. Overlaps with Unimedic's distribution activities in Sweden, Finland and the wider Nordics.
- Tamro (PHOENIX Group): One of the leading pharmaceutical wholesalers in the Nordics, distributing medicines and health products across Sweden, Finland, Norway and the Baltics. Directly comparable to Unimedic's Nordic pharmaceutical distribution function.
- Moberg Pharma AB: Swedish specialty pharma company commercializing proprietary niche pharmaceutical products (primarily dermatology). Similar Nordic commercialization approach and proprietary product focus, although different therapeutic area.
- AcuCort AB: Small Swedish specialty pharma developing proprietary pharmaceutical products and using Unimedic as its Nordic distribution partner. Comparable in therapeutic focus areas and Nordic commercialization model, though smaller in scale.
- Orifarm Group: Danish-based specialty pharma company focused on parallel import, generics and proprietary products across the Nordics and Europe. Comparable Nordic positioning and mix of proprietary and partner-led distribution.
Broad incumbents
- Sobi (Swedish Orphan Biovitrum): Sweden's largest specialty pharma company, focused on rare diseases and specialty therapeutics with significant Nordic presence. Operates in overlapping therapeutic areas but at substantially larger scale and with a global footprint.
- Viatris Inc. Global specialty and generic pharmaceutical major with significant Nordic footprint, whose products are distributed by Unimedic in the region. Operates in overlapping therapeutic areas but at vastly larger scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
Unimedic Pharma social profiles
Digital presenceUnimedic Pharma compliance and trust
Trust signalCompliance2 records
Unimedic Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Unimedic Pharma leadership team
Management profileNumber of profiles
Profiles13 records
Unimedic Pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
Unimedic Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Unimedic Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Unimedic Pharma
What does Unimedic Pharma do?
Unimedic Pharma is a Swedish specialty pharmaceutical company that commercializes registered specialty pharmaceuticals, partner products, and unlicensed pharmaceuticals across the Nordic region (Sweden, Norway, Finland, Denmark). The company specializes in registering, launching, and marketing pharmaceuticals on the Nordic market through an integrated platform covering regulatory affairs, market access, distribution, marketing, quality assurance, pharmacovigilance, and field-based sales, and operates Unimedic AB, an in-house CDMO for liquid pharmaceutical manufacturing.
Is Unimedic Pharma a public or private company?
Unimedic Pharma is a private company. It is classified as corporate owned and is currently operating.
When was Unimedic Pharma founded?
Unimedic Pharma was founded in 1992. It employs 11 to 50 people.
Where is Unimedic Pharma based?
Unimedic Pharma is headquartered in Stockholm, Sweden, in the Europe region.
How does Unimedic Pharma make money?
Four revenue lines are on record. Registered Specialty Pharmaceuticals Sales are the primary driver. The others are unlicensed Pharmaceuticals Distribution, out-licensing of Proprietary Products and commercial Partnership Representation (MAH/Agent).
Who are Unimedic Pharma's main competitors?
Direct peers on record are Orexo AB, Camurus AB, Recipharm AB, Oriola Corporation, Tamro (PHOENIX Group), Moberg Pharma AB, AcuCort AB and Orifarm Group. Broad incumbents are Sobi (Swedish Orphan Biovitrum) and Viatris Inc..
Does Unimedic Pharma have an API?
No public API is recorded for Unimedic Pharma.